At present, programmed death‐1 (PD‐1), programmed death ligand 1 (PD‐L1) and cytotoxic T lymphocyte associated protein 4 (CTLA4), which mediate critical pathway responsible of immune-tolerance against tumor cells, are the major therapeutic target of ICIs therapy (Gunturi and McDermott, 2014; Del Paggio, 2018). The gene discussed is CTLA4; the disease is neoplasm.